RESUMO
Combating antibiotic resistance has found great interest in the current clinical scenario. Pseudomonas aeruginosa, an opportunistic multidrug-resistant pathogen, is well known for its deadly role in hospital-acquired infections. Infections by P. aeruginosa are among the toughest to treat because of its intrinsic and acquired resistance to antibiotics. In this study, we project gallium-curcumin nanoparticle (GaCurNP) conjugates as a prospective candidate to fight against P. aeruginosa. The synthesized GaCurNPs were spherical with an average size ranging from 25-35 nm. Analysis by Fourier transform infrared (FT-IR) spectroscopy, Raman spectroscopy, and X-ray photoelectron spectroscopy deduced the nature of interaction between gallium and curcumin. Conjugate formation with gallium was found to improve the stability of curcumin at the physiological pH. When tested after 24 h of contact, at the physiological pH and 37 °C, the degradation of curcumin bound in the GaCurNPs was 26%, while that of native curcumin was 95%. The minimum inhibitory concentration (MIC) of GaCurNPs was found to be 82.75 µg/mL for P. aeruginosa (ATCC 27853). GaCurNPs also showed excellent biofilm inhibition at 4MIC concentration. Raman spectroscopic analysis showed that GaCurNPs are capable of disrupting the cells of P. aeruginosa within 3 h of contact. Live/dead imaging also confirmed the compromised membrane integrity in cells treated with GaCurNPs. Scanning electron microscopy analysis showed membrane lysis and cell structure damage. The AlamarBlue assay showed that when L929 cell lines were treated with GaCurNPs with concentrations as high as 350 µg/mL, the cell viability elicited by the nanoparticles was 70.89%, indicating its noncytotoxic nature. In short, GaCurNPs appear to be a promising antibacterial agent capable of fighting a clinically significant pathogen, P. aeruginosa.
